Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00666588 · ClinicalTrials.gov registry record · Phase 2
Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
NCT00666588: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00666588 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 52 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00666588, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
Study Summary
This phase II trial is studying the side effects and best dose of bortezomib and to see how well it works when given together with combination chemotherapy in treating younger patients with recurrent, refractory, or secondary acute myeloid leukemia (AML). Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as idarubicin, cytarabine, and etoposide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) together with bortezomib may kill more cancer cells
Interventions
- OTHER laboratory biomarker analysis
- DRUG etoposide
- DRUG cytarabine
- DRUG idarubicin
- DRUG bortezomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2008-04 |
| Est. Completion | 2012-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00666588
The ClinicalTrials.gov registry entry for NCT00666588 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT00666588 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00666588 about?
NCT00666588 is a clinical study titled "Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia". This phase II trial is studying the side effects and best dose of bortezomib and to see how well it works when given together with combination chemotherapy in treating younger patients with recurrent, refractory, or secondary acute myeloid leukemia (AML). Bortezomib may stop the growth of cancer cel...
What is the current status of trial NCT00666588?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2008-04. Estimated completion is 2012-12.
What interventions are being tested in trial NCT00666588?
The interventions under investigation include: laboratory biomarker analysis (OTHER), etoposide (DRUG), cytarabine (DRUG), idarubicin (DRUG), bortezomib (DRUG).
Who is sponsoring clinical trial NCT00666588?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.